Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shiv K Gupta

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Molecular Cancer Therapeutics|January 15, 2024
Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis XenograftsJianxiong Ji, Sonja Dragojevic, Cameron M Callaghan, et al.
Journal of the National Cancer Institute|November 29, 2015
Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of GlioblastomaShiv K Gupta, Sani H Kizilbash, Brett L Carlson, et al.
Neuro-Oncology|April 15, 2025
The novel brain penetrant ATM inhibitor WSD0628 provides robust radiosensitization of brain tumor patient derived xenograftsZhiyi Xue, Ann C Mladek, Sneha Rathi, et al.
Neuro-Oncology Advances|September 8, 2022
Convection enhanced delivery of EGFR targeting antibody-drug conjugates Serclutamab talirine and Depatux-M in glioblastoma patient-derived xenograftsKendra A Porath, Michael S Regan, Jessica I Griffith, et al.
Molecular Cancer Therapeutics|October 23, 2024
DNA-PK Inhibition Shows Differential Radiosensitization in Orthotopic GBM PDX Models Based on DDR Pathway DeficitsSonja Dragojevic, Emily J Smith, Michael S Regan, et al.
Neuro-Oncology|July 27, 2019
Molecular profiling of long-term IDH-wildtype glioblastoma survivorsDanielle M Burgenske, Jie Yang, Paul A Decker, et al.
Nature Communications|November 23, 2018
Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastomaElizabeth C Randall, Kristina B Emdal, Janice K Laramy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2025
Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH-Wild-type GlioblastomaRachael A Vaubel, Wenjuan Zhang, Ju-Hee Oh, et al.
Neuro-Oncology|May 29, 2021
Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastomaBianca-Maria Marin, Kendra A Porath, Sonia Jain, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Molecular Cancer Therapeutics|January 15, 2024
Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis XenograftsJianxiong Ji, Sonja Dragojevic, Cameron M Callaghan, et al.
Journal of the National Cancer Institute|November 29, 2015
Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of GlioblastomaShiv K Gupta, Sani H Kizilbash, Brett L Carlson, et al.
Neuro-Oncology|April 15, 2025
The novel brain penetrant ATM inhibitor WSD0628 provides robust radiosensitization of brain tumor patient derived xenograftsZhiyi Xue, Ann C Mladek, Sneha Rathi, et al.
Neuro-Oncology Advances|September 8, 2022
Convection enhanced delivery of EGFR targeting antibody-drug conjugates Serclutamab talirine and Depatux-M in glioblastoma patient-derived xenograftsKendra A Porath, Michael S Regan, Jessica I Griffith, et al.
Molecular Cancer Therapeutics|October 23, 2024
DNA-PK Inhibition Shows Differential Radiosensitization in Orthotopic GBM PDX Models Based on DDR Pathway DeficitsSonja Dragojevic, Emily J Smith, Michael S Regan, et al.
Neuro-Oncology|July 27, 2019
Molecular profiling of long-term IDH-wildtype glioblastoma survivorsDanielle M Burgenske, Jie Yang, Paul A Decker, et al.
Nature Communications|November 23, 2018
Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastomaElizabeth C Randall, Kristina B Emdal, Janice K Laramy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2025
Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH-Wild-type GlioblastomaRachael A Vaubel, Wenjuan Zhang, Ju-Hee Oh, et al.
Neuro-Oncology|May 29, 2021
Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastomaBianca-Maria Marin, Kendra A Porath, Sonia Jain, et al.
Pageof 4